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The in vitro activities of ABT-773 were evaluated against 15 Listeria monocytogenes strains and 196 coryne-
form bacteria isolated from clinical samples. One hundred percent of the L. monocytogenes strains were
inhibited by <0.015 g of ABT-773/ml. MICs of ABT-773 (g/ml) at which 50% of the isolates tested were
inhibited (MIC50s) and MIC90s for other organisms were 0.125 and 0.5 (Corynebacterium amycolatum), 1 and
>32 (Corynebacterium jeikeium), 0.03 and >32 (Corynebacterium minutissimum), >32 and >32 (Corynebacterium
pseudodiphtheriticum and Corynebacterium urealyticum), 0.125 and >32 (Corynebacterium striatum), and 0.03 and
0.5 (Rhodococcus equi), respectively.
Two relevant aspects related to coryneform bacteria have
become significant during the last decade: the recognition of
the medical importance of some species, including Corynebac-
terium jeikeium, Corynebacterium urealyticum, Corynebacterium
striatum, Corynebacterium amycolatum, and Corynebacterium
minutissimum, and the changes in the taxonomy of these or-
ganisms leading to the recognition of a large number of new
species and the redefinition of already known organisms (1, 2,
4, 6, 8). It is critical that studies of the activities of antimicro-
bial agents be based on testing microorganisms identified ac-
cording to the new taxonomic criteria, in order to really obtain
clinically significant information and to allow the comparison
of data obtained from different laboratories (3, 5, 13, 19, 24).
Unfortunately, there is yet no standardized methodology for
susceptibility testing of coryneform bacteria. The NCCLS has
not defined breakpoints for clinical categories of antimicrobial
agents against coryneform bacteria, and in the case of Listeria
spp. only the category of susceptibility to ampicillin and peni-
cillin has been suggested (16). There is scant information on
the activities of antimicrobial agents against coryneform bac-
teria (4–6, 9). C. jeikeium, C. urealyticum, and C. amycolatum
are usually multiresistant organisms, and only glycopeptides
remain universally active against these species (4–6, 18, 19, 22,
23). Some reports suggest that other species may be susceptible
to commonly used antimicrobial agents, but we lack reliable
clinical evidence supporting these in vitro observations. It is
necessary to evaluate the activities of new antimicrobial agents
against coryneform bacteria of clinical importance (3, 7, 10–12,
19).
It has been shown previously that ketolides show a broader
spectrum of activity than do reference macrolides, being active
against macrolide-susceptible gram-positive cocci and against
gram-positive organisms in which macrolide resistance is
caused by active efflux or inducible production of methylase
(21). In a previous study we showed that the new ketolide
telithromycin was more active than were 14- and 16-membered
macrolides, azithromycin, or clindamycin against many coryne-
form bacteria and had high in vitro activity against Listeria
monocytogenes (10). The objective of this study was to evaluate
the in vitro activities of ABT-773 in comparison with other
compounds against L. monocytogenes and different species of
coryneform bacteria isolated from clinical samples.
Two hundred eleven organisms isolated from clinical sam-
ples at the Department of Clinical Microbiology, University
Hospital Virgen Macarena, Seville, Spain, were evaluated, in-
cluding the following species (number of strains): L. monocy-
togenes (15), C. amycolatum (40), C. jeikeium (40), C. minutis-
simum (14), Corynebacterium pseudodiphtheriticum (12), C.
striatum (40), C. urealyticum (40), and Rhodococcus equi (10).
Microorganisms were identified according to the method of
Funke et al. (4), by using API-CORYNE strips and additional
phenotypic tests when necessary. After identification, organ-
isms were maintained in tryptic soy broth–10% glycerol at
80°C. The following reference strains were also tested: C.
jeikeium ATCC 43734, C. striatum ATCC 6940, and C. urea-
lyticum ATCC 43042. Staphylococcus aureus ATCC 29213 and
Enterococcus faecalis ATCC 29212 were used as control strains
for susceptibility testing assays. The following compounds
were studied: ABT-773 (Abbott), cefuroxime (Sigma), clinda-
mycin (Sigma), co-trimoxazole (Gayoso, Madrid, Spain),
erythromycin (Sigma), and vancomycin (Sigma). Solutions of
antimicrobial agents were prepared on the same day as testing,
according to the manufacturer’s instructions. The MICs of the
above-indicated antimicrobial agents were determined, as pre-
viously described, by in-house microdilution according to NC-
CLS guidelines (15, 16), with the exception that, when C.
jeikeium and C. urealyticum (lipophilic organisms) were tested,
the broth was supplemented with 0.5% Tween 80 (Difco, De-
troit, Mich.). Plates were inoculated with a suspension (ap-
proximately 5  105 CFU/ml) in Mueller-Hinton broth (plus
0.5% Tween 80 in the case of C. jeikeium and C. urealyticum)
prepared from bacteria grown on Columbia agar with 5%
sheep blood for 24 to 48 h. Plates were incubated, after inoc-
* Corresponding author. Mailing address: Department of Microbi-
ology, School of Medicine, University of Seville, Apdo. 914, 41080
Seville, Spain. Phone: 34 95 500 8287. Fax: 34 95 437 7413. E-mail:
lmartin@us.es.
1403


























ulation, at 35°C for 20 to 24 h, or (in the case of C. jeikeium and
C. urealyticum) for up to 48 h, to allow bacterial growth in
control (antibiotic-free) wells of the microtiter plate.
The activities of the agents herein tested have been consid-
ered in terms of MIC50s (MICs at which 50% of the isolates
tested are inhibited), MIC90s, and MIC ranges (Table 1). Ad-
ditionally, the numbers and percentages of strains inhibited at
each concentration of ABT-773 and the related drugs eryth-
romycin and clindamycin have also been determined (Table 2).
All strains of L. monocytogenes were inhibited by 0.015 g of
ABT-773/ml. MIC90s of ABT-773 were 32- and 128-fold
lower than those of erythromycin and clindamycin, respec-
tively. Interestingly, this value is also much lower than that
recently obtained in our laboratory for telithromycin, for which
the MIC50 and MIC90 were 0.125 and 0.25 g/ml, respectively.
Our results are similar to those obtained in a previous study
(17), in which all 24 strains of L. monocytogenes were inhibited
at 0.03 g/ml. This good in vitro activity of ABT-773 against L.
monocytogenes contrasts with its relatively high effective dose
(100.1 mg/kg of body weight/day) in an animal model of sepsis
caused by L. monocytogenes (14). Vancomycin and co-trimox-
azole also showed good in vitro activities against L. monocy-
togenes. ABT-773 inhibited higher percentages of strains of all
Corynebacterium species and of R. equi evaluated than did
erythromycin. At a concentration of 0.5 g/ml (the breakpoint
of susceptibility for erythromycin against Staphylococcus spp.)
the percentages of inhibition by ABT-773 and erythromycin
were 92.5 and 15.0% for C. amycolatum, 90.0 and 60.0% for R.
equi, 62.5 and 20.0% for C. striatum, 50.0 and 37.5% for C.
minutissimum, 47.5 and 2.5% for C. jeikeium, 33.3 and 25.0%
for C. pseudodiphtheriticum, and 7.5 and 5.0% for C. urealyti-
cum, respectively. Clindamycin was even less active than eryth-
romycin against the tested strains. We have previously evalu-
ated the activities of telithromycin against coryneform
bacteria, with the same methodology used in this study (10).
ABT-773 showed an activity similar to that of telithromycin
against coryneform bacteria, except in the case of C. striatum,
for which the MIC50 and MIC90 of telithromycin (0.03 and 0.06
g/ml, respectively) were lower than those of ABT-773 (0.125
and 32 g/ml, respectively). The actual reasons for the dif-
ference in the activities of the two ketolides against C. striatum
are presently unknown. It could well be that ABT-773 is in-
trinsically less active than telithromycin is against this organ-
ism, but since the isolates evaluated in this study were more
recent than those in the study with telithromycin, the observed
lower susceptibility of C. striatum to ABT-773 could be due to
a recent increase in the level of resistance of C. striatum to
ketolides, a situation already described for fluoroquinolones
(11).
The differences in susceptibilities to ABT-773 and to eryth-
romycin in the tested strains indicate that macrolide-resistant
coryneform bacteria are still inhibited by ketolides. The mech-
anisms underlying this observation remain undefined, since the
mechanisms of resistance to both macrolides and ketolides in
coryneform bacteria are poorly known. The ermC gene has
been reported to be present in most C. striatum strains resis-
tant to erythromycin (20). The existence of bimodal popula-
tions among C. minutissimum, C. pseudodiphtheriticum, C. stri-
atum, and C. urealyticum suggests that these species may
TABLE 1. Ranges, MIC50s, and MIC90s of antimicrobial agents for
L. monocytogenes and coryneform bacteria





ABT-773 0.015 0.015 0.015
Erythromycin 0.125–0.5 0.25 0.5
Clindamycin 0.5–2 2 2
Co-trimoxazole 0.015–0.03 0.015 0.03
Vancomycin 0.5–1 1 1
C. amycolatum (40)
ABT-773 0.015–2 0.125 0.5
Erythromycin 0.06–128 16 128
Clindamycin 0.25–64 64 64
Cefuroxime 0.03–128 0.25 0.5
Co-trimoxazole 0.25–16 16 16
Vancomycin 0.25–1 0.5 0.5
C. jeikeium (40)
ABT-773 0.015–32 1 32
Erythromycin 0.06–128 128 128
Clindamycin 0.25–64 64 64
Cefuroxime 0.06–64 64 64
Co-trimoxazole 0.125–16 16 16
Vancomycin 0.5–1 0.5 1
C. minutissimum (14)
ABT-773 0.015–32 0.03 32
Erythromycin 0.06–128 32 128
Clindamycin 0.06–64 64 64
Cefuroxime 0.06–64 0.5 32
Co-trimoxazole 0.06–16 2 16
Vancomycin 0.125–1 0.25 0.5
C. pseudodiphtheriticum
(12)
ABT-773 0.015–32 32 32
Erythromycin 0.06–128 128 128
Clindamycin 0.03–64 64 64
Cefuroxime 0.03–1 0.125 0.5
Co-trimoxazole 0.5–16 4 16
Vancomycin 0.25–0.5 0.25 0.25
C. striatum (40)
ABT-773 0.015–32 0.125 32
Erythromycin 0.06–128 8 128
Clindamycin 1–64 64 64
Cefuroxime 0.5–64 2 4
Co-trimoxazole 0.5–16 4 8
Vancomycin 0.125–0.5 0.25 0.25
C. urealyticum (40)
ABT-773 0.015–32 32 32
Erythromycin 0.06–128 128 128
Clindamycin 0.125–64 64 64
Cefuroxime 64 64 64
Co-trimoxazole 16 16 16
Vancomycin 0.125–1 0.5 0.5
Rhodococcus equi (10)
ABT-773 0.015–4 0.03 0.5
Erythromycin 0.06–128 0.5 128
Clindamycin 0.125–64 4 64
Cefuroxime 0.5–64 8 64
Co-trimoxazole 0.25–16 16 16
Vancomycin 0.5 0.5 0.5
a Following the NCCLS suggestion (16), MICs of cefuroxime against L. mono-
cytogenes are not detailed.
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express a similar determinant of resistance, but further studies
are obviously needed in this area.
All coryneform bacteria evaluated were inhibited by 1 g of
vancomycin/ml, in agreement with previous studies (10, 19, 23).
On the other hand, co-trimoxazole was poorly active against
coryneform bacteria, and for this agent all MIC50s against C.
amycolatum, C. jeikeium, and C. urealyticum were 16 g/ml.
MIC50s of co-trimoxazole were higher than 2/38 g/ml (the
breakpoint for staphylococci that may be considered as a ref-
erence indicator) for C. pseudodiphtheriticum, C. striatum, and
R. equi. Cefuroxime was also poorly active in vitro against most
coryneform bacteria. Cefuroxime showed good in vitro activi-
ties against C. amycolatum (MIC90, 0.5 g/ml), C. pseudodiph-
theriticum (MIC90, 0.5 g/ml), and to a lesser extent C. striatum
(MIC90, 4 g/ml). Although the same percentages of C. amy-
colatum and C. striatum strains were inhibited by 8 g of
cefuroxime/ml (100%), this compound was more active against
the former species, because the percentages of inhibition at 0.5
g/ml were 92.5% for C. amycolatum and 5% for C. striatum.
In conclusion, ABT-773 shows very good in vitro activity
against L. monocytogenes and also inhibits a significant number
of coryneform bacteria of clinical relevance. ABT-773 shows
good in vitro activities against C. amycolatum and R. equi and
moderate activities against C. minutissimum and C. striatum
and the multiresistant species C. jeikeium. ABT-773 is poorly
active against C. pseudodiphtheriticum and C. urealyticum.
This study was supported by a grant from Abbott Laboratories.
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